Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07007195

Smart Olfaction App to Reduce Relapse

The proposed project aims to refine and test a novel biobehavioral smoking cessation intervention that integrates the strategic application of olfactory stimulation to reduce cigarette craving with an established smartphone-based smoking cessation application. The specific aims of this study are: (1) refine the design and methodology of our olfactory stimulation delivery system (OSDS) and (2) compare, in a pilot randomized controlled trial (RCT), the effects of a smartphone based app for smoking cessation (Smart-T) with and without the OSDS on smoking cessation outcomes.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

RESTORE Laboratory: Research on Emotion, Substance Use Treatment Outcomes, Rehabilitation, and Empowerment

Houston, Texas, 77204, United States

Location status: Recruiting

Location contact

Lorra Garey, Ph.D.

CONTACT

[email protected]

713-743-8056

About this study

The objective of the current trial is to refine a novel biobehavioral smoking cessation intervention that integrates the strategic application of olfactory stimulation to reduce cigarette cravings (olfactory stimulation delivery system; OSDS) and then to test the OSDS as an adjunctive support for smoking cessation when integrated with an established smartphone-based smoking cessation application (Smart-T).

The study will be conducted in two phases. Phase I will consist of a crossover, micro-randomized controlled trial to inform methodology for odor administration and examine the effects of OSDS on craving reduction. Treatment-seeking smokers (N=32) will engage in a self-guided quit attempt and use the OSDS for 14 days. Using a crossover randomization design, participants will complete 7 days of ad libitum OSDS use and 7 days of instructed OSDS use. Participants will complete an initial online pre-screener, an enrollment call, a baseline survey via the app, a randomization call, and 5 daily EMAs during the study. At the end of Phase I, participants will complete a qualitative interview over Zoom and a quantitative survey in the app to assess their experiences. Phase II will be a RCT in which participants (N=100) will be randomized to either (1) Smart-T with a nicotine patch (Smart-T) or (2) Smart-T with a nicotine patch and OSDS as an adjunctive feature (Smart-T+O). Participants will complete a baseline assessment, daily EMAs for 13 weeks (1-week pre-quit and 12 weeks post-quit), a follow-up assessment at 12 weeks post-quit via the app, and a qualitative interview over Zoom. All participants will have access to Smart-T intervention materials for smoking cessation. Smoking status will be biochemically verified at multiple time points using a Carbon Monoxide monitor, which will be mailed to participants along with usage instructions.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 18 years of age
  • Ability to read, understand and speak English
  • Currently smoke at least 5 cigarettes daily for one year or longer
  • Do not currently smoke marijuana or currently smoke marijuana but willing to not smoke during the duration of the study
  • Did not use electronic cigarette or vaping device in the past 90 days
  • Have an active smartphone that is Apple or Android based
  • Have phone service including a data plan
  • Interested in downloading the study app onto their personal phone
  • Motivated to quit smoking
  • English literacy of 7th grade or higher, as indicated by a score of ≥ 4 on the Rapid Estimate of Adult Literacy in Medicine-Short Form (REALM-SF)
  • Biochemical verification of smoking status
  • Proof of smoking status at enrollment via photo of cigarettes
  • Presents a photo ID that matches the information on screener survey
  • Willing and able to complete study procedures
  • Willing to use NRT and quit smoking for 14 days (Phase I) or willing to use NRT and quit smoking for 13 weeks (Phase II)

Exclusion criteria

  • Olfactory dysfunction including inability to smell, a very weak or distorted sense of smell, or sensitivity to odors
  • Report any allergies or negative reactions to odors/fragranced products
  • Being pregnant, breastfeeding, or planning to become pregnant within the next month
  • Report hypertension that is not under control
  • Have had a heart attack within the past two weeks
  • Those who participated in Phase I will not be eligible to participate in Phase II
  • Have a smartphone that is not compatible with the Insight mHealth platform
  • Report using electronic cigarette or vaping device in the past 90 days

Treatment and study plan

Ad Libitum Use followed by Instructed Use of the Inspire Device

Device

Participants in this condition will use the novel olfactory stimulation delivery system (Inspire), to smell a specific order designed to assist with smoking cessation for 7 days. Participants will then be instructed to record every urge to smoke and report times when they think they might smoke in the smartphone-based smoking cessation app, Insight™. When urges above 0 are reported, the app will instruct participants to use the Inspire device. On day 8, participants will receive a notification on the smartphone-based smoking cessation app, Insight™, to switch to the Instructed Use condition. Participants will then be instructed to use the Inspire device only when participants report a cigarette craving above 0 at each of the surveys prompted from the smartphone-based smoking cessation app, Insight™.

Instructed Use followed by Ad Libitum Use of the Inspire Device

Device

Participants in this condition will use the novel olfactory stimulation delivery system (Inspire), to smell a specific order designed to assist with smoking cessation for 7 days. Participants will be instructed to use the Inspire device only when participants report a cigarette craving above 0 at each of the surveys prompted from the smartphone-based smoking cessation app, Insight™. On day 8, participants will receive a notification on the smartphone-based smoking cessation app, Insight™, to switch to the Ad Libitum condition. Participants will then control how often they use Inspire and will be instructed to record every urge to smoke and report times when they think they might smoke in the smartphone-based smoking cessation app, Insight™.

Smart-T Smoking Cessation App with the Inspire Device Condition

Device

Smart-T provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempts. Smart-T app contains multiple components, including an EMA delivery and data transfer system, automated messages based on EMA responses, and on-demand content. Participants will use Smart-T for 13 weeks. Participants will also use the Inspire device.

Smart-T Smoking Cessation App Without the Inspire Device Condition

Device

Smart-T provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempts. Smart-T app contains multiple components, including an EMA delivery and data transfer system, automated messages based on EMA responses, and on-demand content. Participants will use Smart-T for 13 weeks.

Nicotine replacement therapy (NRT)

Drug

NRT patches will be provided to assist with cravings and withdrawal symptoms following the quit attempts.

Inspire Device

Device

The Inspire Device is a novel olfactory stimulation delivery system. It is a self-contained system with seven sealed chambers, with six gel matrix's that contain a distinct odor and one odorless gel matrix. Participants will press a button on the device to release an odor for participants to smell.

Primary outcomes

  1. OSDS Use

    Time frame: Phase I: Post randomization to End of Study (14 days post-quit date)

    Descriptive data regarding use times and frequency will be assessed.

  2. Odor Assessment

    Time frame: Phase I: Post randomization to End of Study (14 days post-quit date)

    Reports of odor assessment will be used to determine if sniffing specific odors reduce craving more than an odor blank.

  3. Craving Reduction

    Time frame: Phase I: Post randomization to End of Study (14 days post-quit date). Phase II: Post randomization to End of Study (12 weeks post-quit date)

    Participants will report craving levels multiple times per day via the app. Reduction in craving levels over time will be analyzed.

  4. Device Acceptability

    Time frame: Phase I: End of Study (14 days post-quit date). Phase II: End of Study (12 weeks post-quit date)

    Participant satisfaction ratings and qualitative feedback. Acceptability will be assessed through post-intervention surveys and qualitative interviews, focusing on perceived usefulness, ease of use, and overall satisfaction.

  5. Smoking Abstinence

    Time frame: Phase II: Randomization to End of Study

    Biochemically confirmed 7-day point prevalence abstinence 12 weeks following the scheduled quit day.

Study contacts

Contact information is provided by the study sponsor or research team.

Lorra Garey, Ph.D.

CONTACT

[email protected]

713-743-8056

Michael Businelle, Ph.D.

CONTACT

[email protected]

405-271-8001

Sponsors and collaborators

Lead sponsor

University of Houston

Other

Collaborators

  • Brown University
  • University of Oklahoma
  • University of Pittsburgh

Registry information

Official study title

An Innovative Digitally-Delivered Olfactory Method for Reducing Cigarette Cravings and Supporting Smoking Cessation

Acronym: SOARR

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jun 5, 2025
Registry last updated
Jul 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.